Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07533708) titled 'A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours' on April 2.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai Henlius Biotech
Condition:
mCRPC or Advanced/Metastatic Solid Tumors
Intervention:
Drug: HLX3902
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: May 25, 2026
Target Sample Size: 48
To know more, visit https://clinicaltrials.gov/study/NCT07533708
Published by HT Digital Content Services with permi...